An Open Label, Multicenter Study, Evaluating the Safety and Imaging Characteristics of 18F-AV-1451 in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, and Subjects With Alzheimer's Disease
Latest Information Update: 29 Aug 2023
At a glance
- Drugs Flortaucipir-F-18 (Primary) ; Florbetapir F 18
- Indications Alzheimer's disease; Cognition disorders
- Focus Diagnostic use
- Sponsors Avid Radiopharmaceuticals
- 20 Jul 2023 Results comparing BIN1 risk allele rs6733839 with APOE4 on interdependency among AD risk factors and biomarkers by applying Bayesian Network (BN) modeling to data from Lilly AD clinical trials (A05C (n=142, NCT01565382), A05E (n=217, NCT02016560), AZES (n=206, NCT02245737), LLCF (n=229, NCT02791191), and LZAX (n=194, NCT01900665) ), presented at the Alzheimer's Association International Conference 2023.
- 20 Jul 2023 Results of pooled analysis from NCT01900665, NCT02791191, NCT02245737, NCT02016560 assessing to understand the direct and indirect effects, mediated through amyloid levels, of the rs6733839 T-allele and APOE e4-allele on tau presented at the Alzheimer's Association International Conference 2023
- 20 Jul 2023 Results presented at the Alzheimer's Association International Conference 2023